On the heels of a sting­ing Q1 set­back, Es­pe­ri­on's long­time cham­pi­on is ex­it­ing the helm and turn­ing the wheel over to a mar­ket­ing pro

Just days af­ter get­ting stung by crit­i­cism from a bad­ly dis­ap­point­ed group of an­a­lysts, there’s a big change hap­pen­ing to­day at the helm of Es­pe­ri­on $ES­PR.

Long­time CEO Tim Mayleben, who cham­pi­oned the com­pa­ny for 9 years from ear­ly clin­i­cal through a lengthy late-stage dri­ve to suc­cess­ful­ly get their cho­les­terol drug ap­proved for a sig­nif­i­cant niche of pa­tients in the US, is out of the C suite, ef­fec­tive im­me­di­ate­ly. Shel­don Koenig — hired at the end of 2020 with a re­sume re­plete with Big Phar­ma CV sales ex­pe­ri­ence —  is step­ping in­to his place, promis­ing to right a bad­ly list­ing com­mer­cial ship that’s been bat­tered by mar­ket forces.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER